Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8675407 | 1.00 | TSHR (0.48) | TSHRSLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL8414022 | 1.00 | TSHR (0.48) | TSHRSLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL8674396 | 1.00 | TSHR (0.48) | TSHRSLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL1265905 | 1.00 | TSHR (0.48) | TSHRSLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL14721383 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3MAOAMAOB | |
| SCHEMBL16422529 | 0.81 | KDM1A (0.37) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL17158493 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3SLC18A3 | |
| SCHEMBL14731159 | 0.81 | ESR2 (0.32) | — | |
| SCHEMBL16422528 | 0.81 | KDM1A (0.37) | SLC6A2SLC6A4SLC6A3MAOBKDM1A | |
| SCHEMBL1195857 | 0.81 | TSHR (0.64) | TSHRSLC6A2SLC6A4SLC6A3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271967-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271967-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271967-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2649069-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2649069-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20130338185-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2649069-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| CN-103194520-A | Method for preparing 4-hydroxyl tetrahydropyran derivative with optical activity through enzymatic transesterification | UNIV NINGXIA | 2013-07-10 | — | — | CN | disclosed |
| WO-2012062750-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062750-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2010064705-A1 | NOVEL 7-SUBSTITUTED DIHYDROPYRANOPYRIMIDINE DERIVATIVE HAVING H4 RECEPTOR ANTAGONISTIC ACTIVITY | 大日本住友製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009124882-A1 | NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124882-A1 | NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| EP-0931139-A1 | IMMOBILIZED COFACTOR-DEPENDENT ENZYMES | McGILL UNIVERSITY (CA) | 1999-07-28 | — | — | EP | disclosed |
| US-5807926-A | OXIDO-REDUCTO SYNTHESIS | MCGILL UNIVERSITY (CA) | 1998-09-15 | — | — | US | disclosed |
| WO-1998016631-A1 | IMMOBILIZED COFACTOR-DEPENDENT ENZYMES | MCGILL UNIVERSITY (CA) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | TSHR 3899/4885SLC6A2 1792/4885SLC6A4 697/4885 |
| US-20130338185-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | TSHR 370/4885SLC6A2 463/4885SLC6A4 354/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | TSHR 3899/4885SLC6A2 1792/4885SLC6A4 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.